An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chit, Ayman ^a,b   Roiz, Julie ^c   Aballea, Samuel ^c  

^a Health Outcomes and Economics North America Sanofi Pasteur ^*  (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CREATIV CEUTICAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BUDGET; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HERD IMMUNITY; HUMAN; INFECTION PREVENTION; INFLUENZA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; ADOLESCENT; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HOSPITALIZATION; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ONTARIO; PHYSIOLOGY; PRESCHOOL CHILD; THEORETICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, THEORETICAL; ONTARIO; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 84941662534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133606     Document Type: Article

References (39)

1. GlaxoSmithKline. FluLaval Tetra Product Monograph. 2014. Available: http://www.gsk.ca/english/docs-pdf/product-monographs/FluLaval-Tetra.pdf.
2. Sanofi Pasteur. Fluzone Quadrivalent Product Monograph. 2014. Available: http://www.sanofipasteur. ca/sites/default/files/sites/default/files/pictures/450-FluzoneQIV-PM-E.pdf.
3. Ambrose CS, Levin MJ.The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012; 8(1):81-88. doi: 10.4161/hv.8.1.17623 PMID: 22252006
4. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007; 25(15):2842-2851. PMID: 17081662
5. Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, et al. Challenge of conductinga placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis. 2009; 9:2. doi: 10.1186/1471-2334-9-2 PMID: 19149900
6. Skowronski DM, De SG, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009; 199(2):168-179. doi: 10.1086/595862 PMID: 19086914
7. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010; 51(9):997-1004. doi: 10.1086/656578 PMID: 20868284
8. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011; 29(38):6558-6563. doi: 10.1016/j.vaccine.2011.07.002 PMID: 21767593
9. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011; 11(1):23-29. doi: 10.1016/S1473-3099(10)70255-3 PMID: 21106443
10. Janjua NZ, Skowronski DM, De SG, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis. 2012; 205(12):1858-1868. doi: 10.1093/infdis/jis283 PMID: 22492921
11. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012; 31(1):49-57. doi: 10.1016/j.vaccine.2012.10.084 PMID: 23142300
12. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013; 11:153. doi: 10.1186/1741-7015-11-153 PMID: 23800265
13. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012; 30(11):1993-1998. doi: 10.1016/j.vaccine. 2011.12.098 PMID: 22226861
14. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012; 30(52):7443-7446. doi: 10.1016/j.vaccine.2012.10.025 PMID: 23084849
15. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014. 10(5): 1171-80. doi: 10.4161/hv.28221 PMID: 24609063
16. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoSOne. 2014. 9(6): e98437. doi: 10.1371/journal.pone.0098437 PMID: 24905235
17. You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014. 14(1): 618.
18. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane rearranged: Support for policies to vaccinate elderly people against influenza. Vaccine 2013 Dec 5; 31 (50):6030-3. doi: 10.1016/j.vaccine.2013.09.063 PMID: 24095882
19. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immu-nogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013 Jan 21; 31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074 PMID: 23228813
20. Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, Johansen H, et al. The effect of universal influenza immunization on mortality and health care use. PLoSMed. 2008 Oct 28; 5(10):e211. doi: 10.1371/journal.pmed.0050211 PMID: 18959473
21. Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, et al. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010 Apr; 7(4): e1000256. doi: 10.1371/journal.pmed.1000256 PMID: 20386727
22. Canadian consumer price index. Statistics Canada 2015: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ161a-eng.htm
23. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza- United States, 1976-2007. MMWRMorb Mortal Wkly Rep. 2010 Aug 27; 59(33):1057-62. PMID: 20798667
24. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 May; 54(10):1427-36. doi: 10.1093/cid/cis211 PMID: 22495079
25. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995Jun; 14(2):171-89. PMID: 10154656
26. Canadian Hourly Labor Costs. Statistics Canada 2015. Available: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69a-eng.htm
27. Organisation for Economic Co-operation and Development. StatExtracts. Unit Labour Costs-Annual Indicators: Labour Compensation per Employee/Hour ($US PPP adjusted) 2013. Available: http://stats. oecd.org/Index.aspx?queryname=430&querytype = view
28. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making. 2012Sep-Oct; 32(5):712-21. PMID: 22990086
29. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010 March 10; 303 (10):943-950. doi: 10.1001/jama.2010.250 PMID: 20215608
30. Langley JM, Krahn M, Husereau D, Spika J, Fisman DN, Chit A, Van Exan R. Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Rev Vaccines. 2014 Nov; 13(11):1291-6 doi: 10.1586/14760584.2014.939637 PMID: 25052459
31. pan Canadian Oncology Drug Review. Canadian Agency for Drugs and Technologies in Health 2015. https://www.cadth.ca/pcodr/find-a-review
32. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013; 310(16):1711-1720. doi: 10.1001/jama.2013.279206 PMID: 24150467
33. Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza illness and hospitalizations averted by influenza vaccination in the united states, 2005-2011. PLoSOne. 2013. 8(6): e66312. PMID: 23840439
34. Statistics Canada. Population and life expectancy estimates. 2013. Available: http://www.statcan.gc. ca/start-debut-eng.html.
35. Pogany L, Barr RD, Shaw A, Speechley KN, Barrera M, Maunsell E. Health status in survivors of cancer in childhood and adolescence. Qual Life Res. 2006 Feb; 15(1):143-57. PMID: 16411038
36. Joint Canada/USA Survey of Health 2002/3 (JCUSH 2002/3). 2003.
37. Schanzer DL, Zheng H, Gilmore J. Statistical estimates of absenteeism attributable to seasonal and pandemic influenza from the Canadian Labour Force Survey. BMC Infect Dis. 2011; 11:90. doi: 10.1186/1471-2334-11-90 PMID: 21486453
38. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003; 7(35):iii-xiii, 1-170. PMID: 14609480
39. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd Edition. 2006.